Edition:
United States

Intellipharmaceutics International Inc (IPCI.OQ)

IPCI.OQ on NASDAQ Stock Exchange Capital Market

1.00USD
20 Oct 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.00
Open
$1.00
Day's High
$1.01
Day's Low
$0.98
Volume
16,001
Avg. Vol
58,248
52-wk High
$3.34
52-wk Low
$0.82

Latest Key Developments (Source: Significant Developments)

Intellipharmaceutics announces US$4 mln registered direct offering
Wednesday, 11 Oct 2017 08:00am EDT 

Oct 11 (Reuters) - Intellipharmaceutics International Inc ::Intellipharmaceutics announces US$4 million registered direct offering.Intellipharmaceutics - ‍entered securities purchase agreements with investors providing for purchase ,sale of 3.6 million shares at US$1.10 per share​.  Full Article

Intellipharmaceutics- Q3 loss per share $0.08
Tuesday, 10 Oct 2017 05:20pm EDT 

Oct 10 (Reuters) - Intellipharmaceutics International Inc :Intellipharmaceutics announces third quarter 2017 results.Q3 loss per share $0.08.Q3 revenue $1.2 million versus $600,000.Intellipharmaceutics International Inc - ‍ expects revenue from generic Seroquel XR to increase going forward​.  Full Article

Intellipharmaceutics receives complete response letter from FDA for Rexista NDA
Monday, 25 Sep 2017 07:00am EDT 

Sept 25 (Reuters) - Intellipharmaceutics International Inc ::Intellipharmaceutics receives complete response letter from the FDA for rexista™ NDA.Intellipharmaceutics receives complete response letter from the fda for rexista™ NDA.Intellipharmaceutics International Inc - ‍Intellipharmaceutics has been given one year to respond to CRL, and can request additional time if necessary.Intellipharmaceutics international inc - ‍fda has also requested that Intellipharmaceutics submit an alternate proposed proprietary name for oxycodone ER​.Intellipharmaceutics -do not expect additional category 2, 3 studies FDA requested will impact anticipated commercialization timeline for oxycodone ER​.  Full Article

Intellipharmaceutics provides operational update on its Rexista(TM) program
Tuesday, 5 Sep 2017 02:35pm EDT 

Sept 5 (Reuters) - Intellipharmaceutics International Inc ::Intellipharmaceutics provides operational update.Currently anticipate Rexista program​ study will take nine months from commencement to complete.Is in process of commencing its planned Category 3 study to support certain label claims for Rexista(TM)​.Trial date for previously announced patent litigation by Purdue against co regarding Rexista(TM) set for Oct 22, 2018​.‍FDA is stayed from granting approval of Rexista until August 24, 2019​.  Full Article

Intellipharmaceutics announces resignation of CFO
Tuesday, 8 Aug 2017 03:00pm EDT 

Aug 8 (Reuters) - Intellipharmaceutics International Inc ::Intellipharmaceutics announces resignation of chief financial officer.Says ‍commenced a search to fill Della Penna's role​.Says ‍announced resignation of Domenic Della Penna, chief financial officer, who is leaving company effective Sept 1.Says ‍pending hiring of replacement for Penna, functions of CFO will be carried out by Amina Odidi​.  Full Article

Intellipharmaceutics says purported class action complaint was filed by Shawn Shanawaz
Monday, 31 Jul 2017 08:00am EDT 

July 31 (Reuters) - Intellipharmaceutics International Inc :Intellipharmaceutics International - on July 28, purported class action complaint was filed in U.S. Court By Shawn Shanawaz.Intellipharmaceutics International - complaint seeks, among other remedies, unspecified damages, equitable and/or injunctive relief.Intellipharmaceutics International-complaint filed by Shanawaz on behalf of himself, all others similarly situated against co & 2 of its executive officers.Intellipharmaceutics - complaint alleges misleading statements or failing to disclose certain info regarding co's new drug application for Rexista.  Full Article

Intellipharmaceutics says committees expressed desire to review additional safety data for Rexista
Wednesday, 26 Jul 2017 08:15pm EDT 

July 26 (Reuters) - Intellipharmaceutics International Inc :Intellipharmaceutics provides update on FDA advisory committees meeting for Rexista™ (oxycodone hydrochloride extended release), an abuse-deterrent opioid analgesic for the treatment of moderate to severe pain.Intellipharmaceutics - Committees expressed desire to review additional safety data for Rexista.Intellipharmaceutics International Inc - Intends to conduct category 3 abuse potential studies for Rexista(tm).Can be no assurance that we will not be required to conduct further studies for Rexista.Intellipharmaceutics International - FDA set a prescription drug user fee act goal date of Sept 25 for completion of its review of Rexista NDA candidate.Intellipharmaceutics International Inc - FDA advisory committee voted 22 to 1 in finding co's nda for Rexista should not be approved at this time.  Full Article

FDA Staff largely supports abuse-deterrent properties of Intellipharma's opioid painkiller
Monday, 24 Jul 2017 09:23am EDT 

July 24 (Reuters) - Intellipharmaceutics International Inc -:FDA Staff: no new safety signals were identified with Intellipharma's opioid painkiller Rexista beyond what is already known for oxycodone products.FDA Staff: Intellipharma's opioid painkiller Rexista tablets are relatively easier to reduce into fine particles than OxyContin tablets.FDA Staff: most solvents had similar or lower extraction recoveries from Rexista tablets than from OxyContin tablets.FDA Staff: at the correct combination of testing conditions, Rexista tablet samples were similar or less syringeable than OxyContin .FDA Staff: not easy to separate/eliminate blue dye & nasal irritant in Rexista, without using extensive chemistry knowledge.FDA Staff: using complex extraction procedures, oxycodone base can be achieved with similar or lower purity & yield from Rexista than from OxyContin .FDA Staff: varying extent of physical manipulations progressively increase the oxycodone dissolution rate from both Rexista and OxyContin .FDA Staff: even with the largest extent of manipulation, Rexista still retained some extended-release characteristics.FDA Staff: Rexista tablets are less efficient to vaporize than OxyContin tablets.  Full Article

Intellipharmaceutics International files short form base shelf prospectus
Tuesday, 18 Jul 2017 06:45am EDT 

July 18 (Reuters) - Intellipharmaceutics International Inc ::Intellipharmaceutics International files short form base shelf prospectus of up to $100 million - SEC filing.  Full Article

Intellipharmaceutics announces Q2 loss per share $0.06
Tuesday, 11 Jul 2017 05:15pm EDT 

July 11 (Reuters) - Intellipharmaceutics International Inc :Intellipharmaceutics announces second quarter 2017 results.Qtrly revenues more than tripled to $2.0 million from $0.6 million.Q2 loss per share $0.06.Had cash of $1.5 million as at May 31, 2017 compared to $2.4 million as at February 28, 2017.Currently expect to satisfy our operating cash requirements until September 2017.  Full Article